Abstract: Linsitinib (OSI-906) is an orally bioavailable, small-molecule tyrosine kinase inhibitor that selectively targets the insulin-like growth factor 1 receptor (IGF-1R) and the insulin receptor (IR). In the context of solid tumor oncology, linsitinib has demonstrated significant potential by suppressing tumor growth and overcoming multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transporters. Clinical evaluations in advanced solid tumors have shown promising antitumor activity, including stable disease and partial or complete responses in specific cancer types. However, its clinical application is challenged by metabolic toxicities, primarily hyperglycemia and insulin resistance, stemming from its dual inhibition of the IR. This review synthesizes the pharmacological activity, molecular mechanisms, limitations, and future perspectives of linsitinib based on recent literature.
1. Introduction
Linsitinib, also known as OSI-906, is a selective, orally efficacious small-molecule tyrosine kinase inhibitor (TKI) [1]. It was primarily developed to target the insulin-like growth factor 1 receptor (IGF-1R) and the insulin receptor (IR), both of which are receptor tyrosine kinases frequently implicated in cancer cell proliferation, survival, and transformation [2]. The IGF-1R and IR pathways are critical drivers in various malignancies, making them attractive targets for solid tumor oncology. Beyond its direct antitumor effects, linsitinib has garnered attention for its ability to reposition as an antagonist of ATP-binding cassette (ABC) transporters, thereby offering a strategy to combat anticancer drug resistance [1]. Furthermore, its mechanism of action has prompted investigations into other IGF-1R-driven pathologies, such as Graves' orbitopathy [4].
2. Pharmacological Activity
Linsitinib exhibits robust pharmacological activity across preclinical and clinical oncology models. In preclinical studies, linsitinib effectively inhibits tumor growth in IGF-1R-driven xenograft mouse models [1][2]. Phase I clinical trials have evaluated both intermittent and continuous oral dosing schedules of linsitinib in patients with advanced solid tumors [2]. These trials demonstrated that the drug is generally well-tolerated and possesses notable antitumor activity. Patients exhibited stable disease across both dosing regimens. Notably, partial responses were observed in patients with adrenocortical carcinoma under intermittent dosing, and a complete response was recorded in a melanoma patient receiving continuous dosing [2].
In addition to its direct antitumor effects, linsitinib acts as a potent reversal agent for multidrug resistance (MDR). It significantly potentiates the cytotoxic effects of anti-neoplastic drugs such as mitoxantrone and SN-38 in ABCG2-overexpressing cancer cells, as well as paclitaxel, docetaxel, and vinblastine in ABCC10-overexpressing cells [1]. Outside of oncology, linsitinib has shown efficacy in phase 2b/3 trials for Graves' orbitopathy (thyroid eye disease), achieving significant proptosis reduction by inhibiting IGF-1-induced cellular proliferation and hyaluronic acid secretion [4][5].
3. Molecular Mechanism of Action
The primary mechanism of action of linsitinib involves the specific inhibition of the autophosphorylation and activation of both IGF-1R and IR [1][3]. By blocking these receptors, linsitinib prevents the ligand-induced activation of critical downstream signaling cascades, including the PI3K/Akt, ERK1/2, and p70S6K/S6 kinase pathways [1][3][4]. This dual inhibition effectively neutralizes the mitogenic and tumor-promoting effects of both IGF1 and IGF2 ligands in cancer cells [2].
Furthermore, linsitinib overcomes MDR by directly antagonizing the efflux function of specific ABC transporters, namely ABCG2 and ABCC10 [1]. Studies utilizing radioactive labeling and immune hybridization have confirmed that linsitinib attenuates ABCG2- and ABCC10-mediated MDR by inhibiting their transport function rather than altering their protein expression levels [1].
4. Structure-Activity Relationship (SAR)
While the provided literature does not detail exhaustive functional group modifications specific to the structure-activity relationship of linsitinib, it highlights the general structural prerequisites for TKIs that act as ABC transporter antagonists. Linsitinib, like other TKIs, is a hydrophobic compound (with calculated logP values typically ranging from 3 to 6) [1]. This hydrophobic character is essential for its interaction with ABC transporters, as the drug-binding sites within the transmembrane domains and ATP-binding domains of these transporters are highly hydrophobic [1]. The ability of linsitinib to distribute within the biomembrane allows it to effectively access and inhibit the efflux pumps, contributing to its dual role as a kinase inhibitor and an MDR reversal agent.
5. Current Limitations
The most significant limitation of linsitinib in clinical application is its metabolic toxicity, which arises directly from its inhibition of the insulin receptor (IR). Systemic inhibition of IR and IGF-1R by linsitinib induces acute insulin resistance [3]. In clinical trials, hyperglycemia emerged as a prominent adverse effect, occurring more frequently in diabetic cohorts, particularly under continuous dosing regimens [2].
Preclinical models further elucidate these metabolic disruptions. Mice treated with linsitinib developed continuous hyperglycemia, hyperinsulinemia, lipodystrophy (lipoatrophy in brown and white adipose tissues), and hepatic steatosis characterized by increased liver weight, triglycerides, and glycogen contents [3]. Additionally, linsitinib administration induced a compensatory increase in pancreatic beta-cell mass and proliferation [3]. Although withdrawal of the drug reverses hyperglycemia, hyperinsulinemia, lipoatrophy, and liver steatosis, the overlapping metabolic roles of IGF-1R and IR make it challenging to target tumors without inducing significant metabolic side effects [3].
6. Future Perspectives
Despite its metabolic limitations, the insulin/IGF system remains a highly relevant target for cancer therapy. Future research must focus on developing strategies to effectively target IGF signaling in tumors while mitigating metabolic toxicity [2]. One potential avenue is the optimization of intermittent dosing schedules, which have shown efficacy and may offer a better therapeutic window regarding glycemic control [2]. Additionally, linsitinib holds significant promise as a supplementary agent in traditional chemotherapy regimens; its ability to inhibit ABCG2 and ABCC10 could be leveraged to overcome multidrug resistance and sensitize refractory tumors to standard antineoplastic drugs [1]. Finally, the identification of specific biomarkers to predict patient sensitivity or resistance to IGF-1R therapies will be crucial for the personalized application of linsitinib in solid tumor oncology [2].
